NCT05737940 (Re-PHIRE) is a Phase 2 clinical trial of AZD3427 in Pulmonary Hypertension (World Health Organization Group 2), sponsored by AstraZeneca.

Who is sponsoring NCT05737940?

NCT05737940 is sponsored by AstraZeneca.

What drugs are being tested in NCT05737940?

Interventions in NCT05737940: AZD3427, Placebo.

Is NCT05737940 still recruiting?

NCT05737940 is currently completed. Last updated 24 September 2025.

Last reviewed 2025-09-24 · How we verify

NCT05737940: Re-PHIRE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of AZD3427 in Participants With Heart Failure and Pulmonary Hypertension Group 2

Completed Phase 2 Last updated 24 September 2025

What this trial tests

Phase 2 trial testing AZD3427 in Pulmonary Hypertension (World Health Organization Group 2) in 260 participants. Completed in 25 August 2025.

Timeline

24 April 2023

Primary endpoint
15 July 2025

25 August 2025

Quick facts

Lead sponsor	AstraZeneca
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	260
Start date	24 April 2023
Primary completion	15 July 2025
Estimated completion	25 August 2025
Sites	60 locations across Denmark, Italy, Japan, Netherlands, Austria, Sweden, United Kingdom, Germany

Drugs / interventions tested

AZD3427 — full drug profile →
Placebo

Conditions studied

Pulmonary Hypertension (World Health Organization Group 2) — all drugs for Pulmonary Hypertension (World Health Organization Group 2) →
Heart Failure — all drugs for Heart Failure →

Sponsor

AstraZeneca — full company profile →

Who can join

Adults 18 to 130, any sex, with Pulmonary Hypertension (World Health Organization Group 2) or Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

A roadmap for therapeutic discovery in pulmonary hypertension associated with left heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function.
Ameri P, Mercurio V, Pollesello P, Anker MS, et al · · 2024 · cited 12× · PMID 38639017 · DOI 10.1002/ejhf.3236
Novel insights and new therapeutic potentials for macrophages in pulmonary hypertension.
Zuo Y, Li B, Gao M, Xiong R, et al · · 2024 · cited 7× · PMID 38555425 · DOI 10.1186/s12931-024-02772-8
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 2024.
Tamargo J, Agewall S, Ambrosio G, Borghi C, et al · · 2025 · cited 6× · PMID 40058879 · DOI 10.1093/ehjcvp/pvaf012
Reassessing Pulmonary Hypertension Classification: Utilizing Criteria for Heart Failure with Preserved Ejection Fraction Instead of Pulmonary Arterial Wedge Pressure.
Park DH, Fuge J, Kamp JC, Harrigfeld B, et al · · 2024 · cited 3× · PMID 39768504 · DOI 10.3390/jcm13247582
Subcutaneous Treprostinil in PH Associated With Left Heart Disease or Chronic Lung Disease.
Sadushi-Koliçi R, Alajbegovic L, Gojic V, Skoro-Sajer N, et al · · 2026 · PMID 41555851 · DOI 10.1002/pul2.70241

Verify or expand the search:

Other trials of AZD3427

Trials testing the same drug.

NCT06611423 — AZD3427 Effects on Renal Perfusion in Heart Failure Patients With Reduced Ejection Fraction and Renal Impairment · Phase 1 · terminated
NCT04890548 — Study to Evaluate the Effects of AZD3427 in Patients With Heart Failure · Phase 1 · withdrawn
NCT04630067 — Assessment of Safety, Tolerability, Immunogenicity, and Pharmacokinetics of AZD3427 · Phase 1 · completed

Other AstraZeneca trials

Trials by the same sponsor.

NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05737940 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 24 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05737940.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing